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Regulation of pre-mRNA splicing is a key process for most if not all eukaryotes. The 
process can, in the abstract, be considered as a series of trans-acting factors that interact 
with cis-motifs in the RNA to enable the removal of introns and joining of exons.  As the 
cis factors need not only be the splice sites themselves, but also motifs in the exons, the 
splicing process has the potential to impose selective constraint on exonic sequence in 
addition to the normal selection on the amino acid content of the protein. To understand 
this more clearly, in this thesis, I mainly focus on a type of important and widely 
investigated cis-motifs, exonic splicing enhancers (ESEs), which bind with SR proteins to 
re-enforce the splice sites and so ensure splicing correctly. First, I explore splice-related 
cis-motif usage of the Ectocarpus genome, which is a species phylogenetically very distant 
from vertebrates but, like vertebrates in having abundant large introns. A deep 
phylogenetic conservation of exonic splice-related constraints is observed (Chapter II). 
Then I extend the analysis across taxa in a phylogenetically explicit framework. In this 
section stronger selection on exon end synonymous sites can be detected within humans 
when the exons are flanked by larger introns. Additionally I report evidence that reduced 
Ne might lead to larger introns and weakened splice sites. Thus I suggest an unusual 
circumstance in which selection (for cis-motifs to control error-prone splicing) might be 
stronger when population sizes are smaller; this is unexpected and would be a necessary 
complement to nearly-neutral theory (Chapter III). Third, I ask whether what we know 
about biases in the usage of ESEs and splicing control elements allows us to understand 
where in human genes pathogenic mutations tend to occur (Chapter IV). By examining the 
relationship between determinants of the usage of splice-associated cis-motifs and the 
distribution of human pathogenic SNPs, I found certain exons are vulnerable to splice 
disruption owing to low ESE density and a “fragile” exon model we proposed could 
describe and explain this phenomenon (Chapter IV). Finally I perform preliminary analysis, 
with a view to biotechnological optimization of transgenes, to address whether there might 
be such a thing as a tissue specific ESE.  To this end I examine ESE usage in tissue 





 A - adenine 
 C – cytosine  
 CAI - Codon Adaptation Index 
 CDS - coding DNA sequence 
 ESE - Exonic Splicing Enhancer 
 ESS - Exonic Splicing Silencer 
 EST - Expressed Sequence Tag 
 G - guanine 
 Ks - synonymous substitution rates 
 MCMC - Markov Chain Monte Carlo 
 mRNA - messenger RNA  
 Ne - effective population size 
 NMD - Nonsense Mediated Decay 
 RESCUE - Relative Enhancer and Silencer Classification by Unanimous Enrichment 
 SNP - Single Nucleotide Polymorphism 
 SR proteins - the serine/arginine-rich proteins 
 T - thymine 
 tRNA - transfer RNA  
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Chapter I. Introduction 
 
In eukaryotes, pre-mRNA splicing, the removal of introns and joining of exons, is 
commonplace in many taxa. In humans for example probably around 97% of protein 
coding genes have at least two exons (Grzybowska 2012). Normally, splicing process 
occurs in spliceosome,  a large ribonucleoprotein (RNP) machine composed of five 
small nuclear ribonucleoprotein (snRNP) complexes (U1, U2, U4/U6, and U5) and 
functions by dynamic assembly and disassembly cycle (Lee and Rio 2015)(Fig. 1). 
Control of splicing is often central to phenotype specification. Splicing patterns of genes in 
the sex determination pathway, for example, define the sex of fruit flies (Grzybowska 
2012). But how are splice sites recognized and how, if at all, does their mode of 
recognition impact on gene evolution?  
 
Previously, exon-intron boundaries were thought to be recognized by simple patterns: AG 
dinucleotide splice acceptor, GT dinucleotide splice donor and an intronic branch site 
(Kent and Zahler 2000; Black 2003) (Fig. 2). In this model there is no exonic specification 
of splice sites beyond the one of two base pairs at the splice site. However, in many taxa 
these features are not sufficient for correct gene splicing and cis-motifs at exon ends 
(within ~70-100bp of splice site) provide reinforcement and definition of the flanking 
splice sites, especially if such sites are “weak” (Berget 1995; Graveley 2000; Fairbrother et 
al. 2002; Dewey, Rogozin, and Koonin 2006; Plass et al. 2008; Cáceres and Hurst 2013). It 
is estimated that in the human genome, approximately 50% of the information defining 
splice sites is in the cis motifs (Lim and Burge 2001).  
 
Two important exonic splicing control elements, serving as enhancers (Exonic Splicing 
Enhancers, ESEs) (Blencowe 2000) and silencers (Exonic Splicing Silencers, ESSs) 
(Amendt, Si, and Stoltzfus 1995; Kan and Green 1999), are considered.  They reside 
within exon ends and affect (promote or inhibit) the exact identification of splice sites by 
interacting with certain protein regulators (SR proteins and hnRNP) (Zheng et al. 2000; 
Rowen et al. 2002) (Fig. 3).  Exon end ESEs generally are under purifying selection 
(Parmley and Hurst 2007).  For example, from substitutional data it is estimated that about 
4-5% of synonymous mutations are under selection in humans because they disrupt ESEs 
(Cáceres and Hurst 2013). Similarly, new point mutations (SNPs) at exon ends are likely to 
be eliminated by purifying selection if they disrupt known motifs (Majewski and Ott 2002; 
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Fairbrother et al. 2004a; Carlini and Genut 2006; Parmley, Chamary, and Hurst 2006; 
Parmley and Hurst 2007; Cáceres and Hurst 2013; Wu and Hurst 2015).  The involvement 
of cis-motifs also distorts codon usage at exonic ends in a manner that is predictable from 
the nucleotide content of splice-associated exonic motifs (Parmley and Hurst 2007; 
Cáceres and Hurst 2013). However, there is little evidence that selection acts upon ESS 
motifs (Chamary, Parmley, and Hurst 2006; Parmley and Hurst 2007; Parmley et al. 2007). 
Thus, in this thesis, I concentrate my attention on ESEs.  
 
Previously researchers have identified candidate ESE sequences by laborious experimental 
methods, for instance, by site-directed mutagenesis of minigene constructs and by 
protocols based on SELEX (Systematic Evolution of Ligands by Exponential enrichment).  
In so doing they have been able to identify several sequences with enhancer activity from a 
pool of random sequences (Tian and Kole 1995; Coulter, Landree, and Cooper 1997; Liu, 
Zhang, and Krainer 1998; Schaal and Maniatis 1999; Liu et al. 2000). Bioinformatics 
methodology revolutionized the hunt for candidate ESEs by, for example, enabling 
understanding the disruption of ESEs through the analysis of disease alleles (Cartegni, 
Chew, and Krainer 2002) and by identification of k-mer sequences that are especially 
abundant near exon ends (Lim et al. 2011). The most commonly employed current 
methodology starts with in silico methods that identify k-mers (typically 6-mers) enriched 
in multiple orthogonal dimensions, followed by experimental validation (RESCUE-ESE) 
(Fairbrother et al. 2002).  Fairbrother et al, for example searched for hexamers enriched in 
exons compared with introns and in exons associated with weak splice sites versus strong 
splice sites (Fairbrother et al. 2002; Fairbrother et al. 2004b). The candidate list of 
hexamers enriched on both dimensions were then subject to experimental testing. 
 
These studies of ESEs have led to a broad consensus as to the properties of ESEs which 
include: 1) ESEs generally locate in the vicinity of splice sites (Berget 1995; Fairbrother et 
al. 2004a) and appear to be functional up to around 70 nucleotides from an exon end 
(Fairbrother et al. 2004a); 2) the main known function of ESEs is enhancing splicing and 
reinforcing recognition of the correct neighbouring splice site (Blencowe 2000; Graveley 
2000), although in some contexts enhancers can behave as silencers for reasons still 
unclear (Ke et al. 2011). 3) ESEs exert influence at the immature RNA level by binding 
with serine and arginine-rich (SR) proteins (Graveley 2000). Generally, these SR proteins 
are 50-300 amino acids in length and composed of two domains, the RNA recognition 
motif (RRM) region and the splicing machinery binding domain, while many unexpected 
functions have been found recently, such as playing roles on RNA transcription, export, 
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translation, and decay (Howard and Sanford 2015). 4) ESEs work by some form of mass 
action as ESE density is typically rather high (using the RESCUE-ESE set of hexamers on 
average 30-40% of sequence near exon ends matches known ESEs (Parmley, Chamary, 
and Hurst 2006)).  5) ESEs may be more prevalent in species with large introns (Warnecke, 
Parmley, and Hurst 2008) and at a higher density at exon ends in proximity to longer 
introns (Dewey, Rogozin, and Koonin 2006; Cáceres and Hurst 2013); 6) ESE sequence is 
likely to be under purifying selection (see above). 7) ESEs tend to be purine enriched 
(Tanaka, Watakabe, and Shimura 1994; Fairbrother et al. 2004a; Parmley et al. 2007; 
Cáceres and Hurst 2013).  In the RESCUE ESE data set for example 50% of nucleotides 
are A, 25% G giving a 75% purine loading. 
 
A major concern is needed here as most of the data pertinent to the impact and properties 
of ESEs comes from mammals, one of the few taxa in which ESEs have been 
experimentally confirmed. How then can we explore the impact of ESEs in non-
mammalian taxa? Importantly, that ESEs have a highly skewed nucleotide usage with a 
strong preference for A and purines more generally, enables us to measure usage of cis 
splice motifs based on nucleotide content at exon ends. Specifically codon usage at exon 
ends is well predicted by underlying nucleotide biases in ESEs (Parmley and Hurst 2007; 
Cáceres and Hurst 2013). This property is useful as it means that we can attempt to 
understand the extent of cis-motif usage in taxa without experimentally defined motifs by 
examining trends in codon and amino acid usage at exon ends.  Indeed, when between-
species variation in exonic cis-motif usage is considered in this thesis, we presume that the 
frequency of distorted codon or amino acid usage in the vicinity of exon junctions is a fair 
measure.  
 
The trend in usage of each codon and amino acid is investigated as a function of the 
distance from the exon–intron boundary up to a distance of 34 codons (to accord with an 
earlier analysis (Warnecke, Parmley, and Hurst 2008)). That is to say, for any given 
species, I consider the usage of any given codon in well-annotated exons, as a function of 
the distance from the boundary.  A codon that is associated with ESEs should be one 
increasing in usage as one approaches the boundary.  By contrast a codon not 
commensurate with ESE usage should be one avoided near exon ends.  I consider typically 
the spearman correlation (rho) between relative codon usage and distance.  A positive rho 
value indicates a codon that is avoided, a negative value one that is preferred near exon 
ends, likely one involved in ESE specification. To ask about the extent to which ESEs are 
used in a species I employ the proportion of codons or amino acids that show significant 
 9 
trends in their usage as a function of the distance from an exon-intron junction.  These 
metrics have been shown, by comparison with reference ESE sets, to correspond well with 
ESE motif usage (Parmley and Hurst 2007; Parmley et al. 2007; Warnecke, Parmley, and 
Hurst 2008; Cáceres and Hurst 2013).  
 
Given the unusual nucleotide content, their high density and their exposure to purifying 
selection, ESE and cis-motif selection more generally has the potential to profoundly 
influence coding sequence evolution.  Here I extend the above findings to address further 
issues in the relationship between ESE functioning and fitness.  In particular I address four 
questions.  First is it generally the case that species with larger introns use ESEs more than 
other taxa?  I examine the case of Ectocarpus in an in depth analysis (Chapter II) and then 
extend the analysis across taxa in a phylogenetically explicit framework (Chapter III). 
Second, given that ESE usage is higher when introns are large, and that introns are large 
when population sizes are small, does it follow that selection for accurate splicing is 
stronger when populations are small (in contradiction of the more common assumption that 
selection is weakest in small populations) (Chapter III)? Third, I ask whether what we 
know about biases in the usage of ESEs and splicing control elements allows us to 
understand where in human genes pathogenic mutations occur (Chapter IV).  Finally I ask 
whether there might be such things as relative tissue specific ESEs (Chapter V). 
 
1.1 Do species with big introns use ESEs more?  
 
The possible connection with intron size mentioned above is central to many aspects of my 
thesis.  Experimental insertion of sequence into introns tends to reduce the rate at which 
the intron is spliced correctly (Klinz and Gallwitz 1985; Luehrsen and Walbot 1992; Fox-
Walsh et al. 2005; Sironen et al. 2006).  Likewise, exons flanked by large introns tend to 
be phylogenetically lost (possibly owing to missplicing) (Kandul and Noor 2009).  
Splicing is also considered more noisy when introns are large (Bell et al. 1998; Fox-Walsh 
et al. 2005).  All this data has led to the notion that large introns are hard to splice 
accurately and so need reinforcement. This reinforcement comes in the form of exonic 
splice enhancers, so explaining the possible coupling with intron size within and between 
genomes. However, the only species with large introns examined to date have been 
mammals.  To understand ESEs usage in phylogenetic perspective, especially for intron-
rich species besides mammals, I start by examining the patterns of codon and amino acid 
usage in the vicinity of exon-intron junctions in the brown algae Ectocarpus siliculosus. 
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This species is unusual in that the genome is well sequenced and annotated (Cock et al. 
2010; Cock et al. 2012)), it is a species with abundant large introns, known SR proteins 
and classical splice sites (Cock et al. 2010) (Chapter II). In this chapter I thus ask how 
common splice-related skews at exonic ends might be in Ectocarpus and how they 
compare with those seen in humans. This provides the first dissection of cis-motif usage in 
a species distant from humans but comparable in genome anatomy. 
 
Aside from simply assessing the commonality of trends, I also attempt to define ESEs for 
this species. The most commonly employed set of human ESEs are those derived by the 
RESCUE-ESE methodology (Fairbrother et al. 2004b), which looks for motifs enriched 
along multiple orthogonal axes. I attempt a similar method to assemble a set of Ectocarpus 
putative ESEs (see method of Chapter II).  I then compare such motifs to human motifs to 
see if there is any resemblance. 
 
As the 3-mer in frame (codons) usage trends in mammals relate to the nucleotide content 
of ESEs (Parmley and Hurst 2007), I also explore, in Ectocarpus, whether exon end codon 
usage bias relates to distribution of ESEs and whether putative hexameric ESEs have 
significant difference with deep phylogenetic SR protein binding motifs. Furthermore, 
given usage trends, in mammals, at the 5‟ and 3‟ ends of exons appear to be largely 
symmetrical (if a codon or amino acid is highly preferred at the 5‟ end of exons, it is 
similarly highly preferred at the 3‟ end) (Warnecke, Parmley, and Hurst 2008; Lim et al. 
2011), but antisymmetry trends were observed in Caenorhabditis worms (Warnecke, 
Parmley, and Hurst 2008), I ask whether symmetry is seen in Ectocarpus. I find that 
Ectocarpus is very rich in ESEs, these ESEs tend to be symmetrical and resemble those 
seen in humans. This suggests very deep conservation of ESEs and that the trend for 
intron-rich species to have many ESEs to be found outside of mammals. 
 
Are splicing optimal and translationally optimal codons mutually exclusive? 
When considering codon usage it is often supposed that one is considering translational 
selection, wherein tRNA usage predicts codon usage, most especially in the most highly 
expressed genes (Duret 2002; Sharp et al. 2005). The codon matching the most abundant 
isoacceptor tRNA is then termed the “optimal” codon.  What is the relationship between 
optimal codons and the distortions of codon usage at exon ends associated with ESEs? 
Prior evidence from Drosophila has suggested that splice optimal and translationally 
optimal codons are mutually exclusive (Warnecke and Hurst 2007). This might make sense: 
As codon usage trends at exon ends is a feature of usage of splicing related cis-motifs, 
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“splicing optimal” codons might be different with “translationally optimal” ones, 
otherwise SR proteins would have difficulty recognizing exclusively exonic ends in highly 
expressed genes. No attempt has been made to consider the generalizability of this result, 
not least because taxa with much ESE usage like humans for the most part do not have 
translationally optimal codons.  In Ectocarpus, by considering trends with respect to 
expression level I found some codons to be “translationally optimal” (Chapter II). 
Ectocarpus thus presents a first new species with abundant ESE usage and translational 
selection. Here then I also make use of Ectocarpus to test the hypothesis that 
“translationally optimal” and “splicing optimal” codons are mutually exclusive. 
 
1.2 Is selection stronger when 'Ne' is low? 
The nearly-neutral theory and its possible complement 
The efficacy of selection depends not only on the extent to which a new allele affects 
fitness, but also on the size of the population into which this mutation is introduced. The 
key variable is the effective population size (Ne) that (Wright 1931) defined as “the number 
of breeding individuals in an idealised population that would show the same amount of 
dispersion of allele frequencies under random genetic drift or the same amount of 
inbreeding as the population under consideration”. The nearly-neutral theory predicts that a 
mutation will be „effectively neutral‟ if its selective disadvantage (s) is negligible 
compared with Ne (more precisely, if s << 1/(2 Ne) for a diploid population) (Ohta 1973; 
Ohta 1992; Ohta 1996). According to this classical theory, there would be relatively low 
levels of selective constraint in species with low Ne (Ohta 1973; Ohta 1992; Ohta 1996).  
Then, as Ne goes down, it becomes harder to eliminate weakly deleterious insertion 
mutations in genomes by purifying selection. This could help us to understand why there is 
more noncoding DNA in human genome than in, for example, the yeast genome (Lynch 
and Conery 2003). 
 
However, this genome decay process may lead to new problems, such as increased 
mistranscription, mistranslation, missplicing, incorrect protein folding, incorrect 
phosphorylation, incorrect subcellular localization etc. (Lynch 2007). These errors might 
necessitate the evolution of protection mechanisms. This means that, as Ne reduces, 
unexpectedly stronger selection may be imposed on error mitigation. We observe that prior 
data suggests that a) introns may be longer when Ne is low (Lynch and Conery 2003) and b) 
that longer introns are associated with a greater need to control splicing, intron size being 
experimentally shown to affect splice accuracy (Klinz and Gallwitz 1985; Luehrsen and 
Walbot 1992; Bell et al. 1998; Fox-Walsh et al. 2005; Sironen et al. 2006; Kandul and 
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Noor 2009).  Thus it might be reasonable to ask whether selection on ESEs is stronger 
when introns are large and populations small. To test this possibility, I focus on selection 
constraints related to splicing error in both intragenomic and intergenomic comparisons 
(Chapter III). 
 
Are more synonymous sites under selection near long introns? 
In our model, introns undergo expansion due to multiple and gradual small insertions, each 
being unable to be resisted by purifying selection if the population is small.  This causes 
increased selection on modifiers of splicing in a ratchet-like process (c.f. Frank 2007). The 
selection to reduce splice error rates we suggest will be manifested, in part, as a higher 
density of exonic cis-modifiers of splicing in proximity to exons with large introns and in 
species with larger introns on the average. 
 
We can employ data from primates to examine the intra-specific prediction. As mentioned 
above, these splicing control cis-motifs are enriched towards the ends of exons 
(Fairbrother et al. 2004a), which in turn cause selective constraint at synonymous sites 
(Carlini and Genut 2006; Parmley, Chamary, and Hurst 2006) and a highly skewed 
nucleotide usage (Tanaka, Watakabe, and Shimura 1994; Fairbrother et al. 2004a; Parmley 
et al. 2007). We thus estimate the proportion of sites at exon ends that are in ESE and 
under purifying selection as a function of intron size.  Determining significance is non-
trivial owing to the skewed nucleotide content of ESEs.  To mitigate this issue, we do 
simulation of randomized pseudoESE sets that are the same size and drawn from the same 
underlying nucleotide content as the true ESE sets. 
 
Do genomes with large introns exonize splicing information? 
To examine the inter-specific predictions we start by re-evaluating the connection between 
Ne.μ and intron size, this being central to our model. From phylogenetically uncontrolled 
correlation based analysis Lynch and Conery (2003) noted that across a wide span of 
species, as Ne.μ declines introns tend to get larger and more common (higher density). Ne.μ 
note is the product of effective population size (Ne) and the mutation rate (μ), the single 
statistic being estimated from population heterozygozity data. The trend in intron size 
Lynch and Conery attribute to weakening selection as Ne declines, i.e. species with low Ne 
are less able to eliminate, via purifying selection, weakly deleterious insertion mutations 
when they occur in introns (and intergenic sequence). This study has, however, been 
criticised for failing to allow for phylogenic non-independence between data points 
(Whitney and Garland 2010). Indeed, it was argued that the key result is not robust to 
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proper phylogenetic control (Whitney and Garland 2010). As this Ne.μ intron size/number 
correlation is a central tenet of the nearly-neutral interpretation of genome anatomy, we 
return to this issue employing a phylogenetically controlled mode of analysis and more up 
to date estimates of Ne.μ, employing both more data and multiple modes of estimation. We 
show that with these updated estimates, in a phylogenetically controlled framework, Ne.μ 
does indeed predict intron dimensions as Lynch and Conery (2003) postulated. We also 
show, however, that Whitney and Garland had an important objection, as we do not 
robustly recover this result using the original Lynch and Conery estimates of Ne.μ.   
 
Given this result, I then move to testing whether ESE usage, intron size and intron density 
covary and whether the trends are predicted by Ne (or rather Ne.μ).  Unexpectedly I 
discover that, in addition to intron size, intron density is a very strong predictor of ESE 
usage and in turn suggest a new synthetic model for which genes/exons and which species 
might be especially enriched for ESEs. 
 
1.3 Does ESE usage predict the intragene location of pathogenic 
mutations? 
The above analyses lead to a synthetic view of which genes and exons have great problems 
splicing correctly and which in turn require more ESEs to reinforce the splicing process.  
Do these predictors in turn enable us to understand where in human genes disease-causing 
mutations occur?  Given, for example, that ESEs function at exon ends, are disease-
causing mutations more common at exon ends? If so how much more common are they 
and with such information can we estimate how many disease causing mutations mediate 
effects via splicing?  
 
In addition, we can ask whether within genes disease-associated mutations are particularly 
associated with ESE rich exons and ESE poor ones or does it make no difference? What 
then more generally is the relationship between determinants of ESEs usage and the 
distribution of pathogenic SNPs. This question is potentially of importance if we wish to 
infer which SNPs might be pathogenic and which not. Given the recognition that even 
synonymous SNPs cause disease, often by disrupting splicing (Faustino and Cooper 2003; 
Chamary, Parmley, and Hurst 2006), converting such insights into improved detection of 
pathogenic SNPs seems like a pressing immediate concern. In order to carry this analysis, I 
consider five correlates of ESEs usages (Chapter IV):  
1) relative position in exons (flank versus core) 
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ESEs are enriched at exon ends and are under selection in these domains. In flanking 
regions of exons, both substitution rates and polymorphism rates are lower than that in 
core regions (Majewski and Ott 2002; Fairbrother et al. 2004a; Carlini and Genut 2006; 
Parmley, Chamary, and Hurst 2006; Parmley et al. 2007; Cáceres and Hurst 2013; Wu and 
Hurst 2015). This is partly explained by richness of functional ESEs in exonic flanks 
(Nelson and Green 1988; Lavigueur et al. 1993; Graveley, Hertel, and Maniatis 1998; 
Fairbrother et al. 2004a; Carlini and Genut 2006; Parmley, Chamary, and Hurst 2006; 
Parmley et al. 2007; Cáceres and Hurst 2013).  
 
2) relative position in genes (5’ versus 3’) 
In a gene, exons at the 5‟ end have more downstream splice sites than ones downstream 
and hence have a larger number of potential decoy splice sites. This logic we speculated 
could explain why exons in 5‟ positions have higher ESE density than that those in 3‟ 
positions.  This is supported by comparison between second exons and last but one exons 
within the same gene. For example, it was observed that there is a 2 fold greater ESE 
density in the former (Wu and Hurst 2015).  
3) flanking intron size 
As mentioned above, species with more abundant large introns tend to have more ESEs 
and exons flanked by larger introns are harder to splice. Given this it is easy to understand 
why ESE density, in the human genome, might be higher in the exons flanked by larger 
introns (Dewey, Rogozin, and Koonin 2006; Cáceres and Hurst 2013; Wu and Hurst 2015). 
4) usage of splice sites (AGgt versus non AGgt)  
I found that usage of tetranucleotide splice sites “AGgt” and “agGT” (the two nucleotides 
in upper case come from exons and those in lower case come from introns) correlates well 
and positively with usage of ESEs across species (Wu and Hurst 2015). This accords with 
prior notions that splice site strength and ESE density coevolve (Fairbrother et al. 2002; 
Dewey, Rogozin, and Koonin 2006).  
5) coding phase of splice site (zero versus non-zero) 
Three possible phases (0, 1, and 2), which show the status of codons at the splice sites (e.g. 
phase zero exons being those cut between whole codons), are found in unequal proportions 
in most genomes (Fedorov et al. 1992; Long, Rosenberg, and Gilbert 1995; Ruvinsky et al. 
2005). In the human genome, a significant relation between coding phases and specific 
splice site (“AGgt” and “agGT”) usage suggests that coding phase could be a predictor of 
ESE density. This is also confirmed by that proportion of phase zero splice site correlates 
well and phylogenetically with metric of cis-motifs usage and intron metrics (mean intron 
size and intron density). 
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I discover that genes with many exons tend to more commonly be disease-causing genes 
(even controlling for CDS length) and that pathogenic mutations are greatly enriched at 
exon ends.  Both of these observations suggest that splice disruption is a key mode of 
pathogenesis. Indeed I estimate that 20-45% of disease associated SNPs disrupt splicing. 
Importantly, for the four other predictors I find that disease-associated mutations tend to be 
associated with exons predicted to have low ESE density.  I confirm this by showing a 
correlation between SNP density and ESE density. Given this I suggest the concept of the 
“fragile” exon, one more easily disrupted by single exon end splice disrupting mutations. 
 
1.4 Splicing related constraints on human tissue-specific genes 
For the most part my thesis has treated all ESEs as equivalent. However some may, for 
example, bind one SR protein better than another. This is almost certainly the case (Liu, 
Zhang, and Krainer 1998; Schaal and Maniatis 1999).  If so, and if SR usage varies by 
tissue, then we might expect that tissue specific ESEs might exist. In my final chapter I 
define a set of human genes that appear to be expressed in only one tissue.  I then employ 
this set to ask whether, within a set of low false positive ESE motifs, some motifs are 
especially abundant at exon ends in genes expressed in only certain tissues.   
 
If such ESEs can be found they are potentially important for transgene engineering.  For 
example, in gene therapy it is desirable for a gene to be correctly expressed often in just 
one tissue. Usage of highly tissue specific promoters can go some way to achieve this.  But 
tissue specific expression is pointless if splicing cannot be done correctly.  Often 
transgenes are synthesized lacking all but the first intron.  It may thus be necessary to 
bolster the first exon with tissue specific splicing information, while removing such 
information (e.g via modification of synonymous sites) from the areas in the gene that 
were in proximity to exon junctions but no near intronic sequence in the transgene.  This 















































Fig. 2 Intronic terminal dinucleotides (5’ GU and 3’ AG) and an branch site 
















Fig. 3 Two important exonic splicing control elements (ESE and ESS) reside within 
exon ends and affect (promote or inhibit) the exact identification of splice sites by 
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Chapter II.   
 
 
Evidence for deep phylogenetic conservation of exonic splice-related 
constraints: splice-related skews at exonic ends in the brown alga 
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Chapter III.   
 
 
Why selection might be stronger when populations are small: intron size 
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Are there tissue-specific ESEs?   
 
Abstract 
In this chapter, some preliminary analysis as regards whether there are tissue-specific 
ESEs show encouraging results for transgenesis and gene therapy. Based on comparison of 
ESE usage patterns, codon usage bias and expression levels between tissue-specific genes, 
I found ESE usage is not a function of expression level. Furthermore, for these tissue-
specific genes, no different ESE usage pattern has been detected between disease 
associated genes and non-disease ones. Interestingly, genes with higher ESE density tend 
to express in more tissues, which indicates tissue-specific genes should have few ESEs, 
meaning it might be possible to delete some ESEs with little effect. While this potential 
application value in practice still needs further scrutiny or even requires experimental 





Previous studies suggest that codons in exon end regions often have at least two functions: 
not simply encoding for proteins in translation but also controlling splicing post-
transcriptionally. For coding, 61 codons are corresponding to amino acids.  Of the 20 
amino acids, 18 have more than one codon specifying them.  Commonly these 
synonymous codons are used unequally, this being codon usage bias (Ikemura 1981). 
Different species show different trends in codon usage bias.  The same is also true when 
comparing genes expressed uniquely in one tissue, that is we see between-tissue within-
species differences in codon usage, although the effect is weak (Plotkin, Robins, and 
Levine 2004; Sémon, Lobry, and Duret 2006). This between-tissue difference in codon 
usage prompted us to ask whether there might also be a difference in cis-motifs usage 
between tissue-specific genes. 
 
In this final chapter I perform some preliminary and exploratory analysis of ESE usage in a 
tissue-specific context. In particular I ask whether, looking at genes expressed in only one 
tissue, I observe different ESEs usage patterns in different tissues. This means both 
whether certain ESEs are used more in certain tissues and whether ESE density varies 
across genes expressed in only one tissue as a function of the tissue.  The main concerns 
here are biotechnological applications rather than evolutionary insights. That is to say, in 
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mouse transgenesis and in human gene therapy, the aim is commonly to replace a non-
functioning gene with a functioning one.  However, as the wild-type gene is often too large 
to be successfully integrated, it is commonplace to remove all but the first intron ( for 
reasons unknown the first intron‟s presence promotes expression) (Klamut et al. 1996; 
Shen et al. 1997; Clancy and Hannah 2002). A challenge is to make sure the transgene is 
expressed in the correct tissue and only in the correct tissue.  Use of tissue-specific 
promoters is here helpful, but might use of tissue specific ESEs also aid the correct 
splicing of the gene only in the tissue concerned?  If we could identify tissue specific ESEs 
we could in principle reinforce the first intron with tissue specific ESEs by modification of 
silent sites. The net aim would be to promote correct splicing in the focal tissue and 
simultaneously to encourage incorrect splicing (including non-splicing) in undesirable 
tissues. Incorrect splicing in a different tissue would likely lead to initiation of the 
nonsense mediated decay pathway, so minimizing the deleterious effect of spurious 
expression.  
 
In principle then we could engineer in tissue specific ESEs and engineer out ESEs that 
might promote splicing in the undesired tissues.  Both can be done via intelligent 
modification of synonymous sites. However, we need also to check for covariates.  Is it for 
example the case that ESE usage varies with expression level – might a highly expressed 
gene, for example, need more ESEs, in which case deletion of ESEs by changing 
synonymous sites might be foolhardy.  Likewise, does ESE density vary by tissue?  If it 
does this might imply again caution against deletion of ESEs in some genes expressed in 
certain tissues. We might a priori expect there to be such differences as a) SR proteins 
show tissue-specific patterns of expression (Jumaa, Guenet, and Nielsen 1997; Liu, Zhang, 
and Krainer 1998), and b) different SR proteins work through different sequences (Liu, 
Zhang, and Krainer 1998). Thus, one of my aims is to look for ESEs with exceptional or 




1. Highly expressed tissue specific genes have the same ESE density as others 
As noted above it would be instructive to know whether gene expression level predicts 
ESE usage as expression level is a key issue for transgene engineering (Emilsson et al. 
2008). Here, we define genes are “tissue-specific” due to their dramatically high 
expression in only one tissue (at least five times higher than the expression in all other 
tissues) (Uhlen et al. 2015). Using this definition we define a relatively small set of genes 
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(indeed much smaller than a much looser definition employed by others (Sémon, Lobry, 
and Duret 2006)). Is there then a correlation between ESE density and expression levels in 
these tissue specific genes?  We employ a strong consensus ESE set (INT3) and a larger 
sample embracing both this consensus set and the RESCUE motifs, these being shown to 
be prototypical ESEs (Cáceres and Hurst 2013). We find that for neither INT3 nor 
INT3+RESCUE datasets is there a correlation between density and expression level 
(Supplementary table S2). This suggests that modification of ESE density is unlikely to 
modify or be modified by expression level.  This is helpful when thinking about deleting 
ESEs via synonymous site modification. 
 
By contrast, based on codon usage preference of ribosomal protein encoding genes, we do 
find there are significant positive correlation between whole CDS codon usage bias (CAI) 
(Sharp and Li 1987) and expression (rho = 0.19, P = 2.06 × 10
-14
) of tissue-specific genes.  
This suggests that highly expressed genes might be under selection to use optimal codons, 
although this finding is contentious in the human context (Francino and Ochman 1999; 
Urrutia and Hurst 2001; Galtier 2003) and control for isochore effects (by far the predictor 
of codon usage profiles in human genes) would be needed to make any strong inference. In 
addition we observe a negative correlation between ESE density and CAI (INT3: rho = -
0.13, P = 1.74 × 10
-7
, INT3+RESCUE: rho = -0.38, P = 2.94 × 10
-57
) (Supplementary table 
S2). This suggests that, for tissue-specific genes, codon usage bias of exon core region 
might predict expression level; and ESE candidates, 6-mer nucleotides sequence which are 
enriched at exon ends, are not used in same manner. Analysis of this issue, including 
isochore control, is left to future study.  Here the main conclusion I wish to draw is that 
ESE usage at exon ends is unaffected by expression level, even if alternative metrics of 
codon usage do so correlate. As a consequence deletion of ESEs in transgenes is unlikely 
to modify expression level. 
  
2. There are differences ESE usage, codon usage and expression levels between tissues 
 
Previous studies suggest different usage patterns of codon usage between tissues, although 
there is a debate about the scale and the analysis method (Plotkin, Robins, and Levine 
2004; Sémon, Lobry, and Duret 2006). One possible reason for this could be relate to the 
usage of tissue specific ESEs which in turn distort codon usage patterns.  Alternatively we 
may be witnessing effects mediated by some other mode of evolution of codon usage 
(possibly a function of expression level). Here then I ask whether there are differences in 
ESE usage, codon usage and expression levels between tissues. I find that ESE density, 
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CAI and expression level all show significant between-tissue heterogeneity (From 
ANOVA: Supplementary table S3). I infer that different genes expressed in certain tissues 
uses ESEs more or less than those employed in other tissues.  As there is no correlation 
between expression level and ESE usage, the heterogeneity in expression level, whilst 
evident, is not an issue as regards engineering tissue specific genes. The CAI variation may 
in part be explained by expression level variation, but again this will need to have isochore 
effects controlled for.  
 
3. Non-homogeneous usage of 6-mer ESE candidates across different tissues 
 
That ESE density varies between tissues is instructive as regards our aim to better design 
transgenes.  But the key issue is whether certain 6-mer ESE candidates are used more in 
certain tissues than others i.e. are some ESEs effectively tissue specific?  Were this true 
then we could engineer these in or out.   
 
In each tissue, I calculated the density of each 6-mer ESE candidate at exon ends based on 
INT3 dataset. To avoid effects of ESEs overlapping, two types of density of each ESE 
were employed, “number of ESEs/length of exon ends” and “number of nucleotides in 
ESEs/length of exon ends”. Some non-homogeneous usage is indeed detected across 
different tissues (Supplementary table S4).  These are best visualized as heatmaps (Fig. 1). 
From this we infer that there are indeed some ESEs that seem to have striking patterns of 
relative tissue specificity.   
 
To express this numerically I employ the entropy measure tau, used before to define tissue 
specificity in expression (see e.g. (Weber and Hurst 2011)). Tau is defined as: 
  
∑    
   )
     )
)    
   
 
where S(j) is the density of the ESE in genes expressed uniquely in tissue j, Smax is the 
maximum density for that ESE across all tissues and n is the number of tissues. Moreover, 
this metric affords us the possibility to check for significance of the tissue specificity. If we 
randomize the numbers across the matrix, we can ask for any given tau value, how often 
we would expect to see tau as big or bigger than that actually reported for any given ESE. 
These results and corresponding tau values are presented in Table 2. From significance test, 
"AAGAAT", "AACCAG", and "AACTGG" show notable tissue specificity.  This comes 
with a severe caveat that none of the significance levels passes multitest correction. 
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4. Genes that express in more tissues have higher ESE density  
A possible corollary of the above finding of relatively tissue specific ESEs, is that genes 
expressed in many tissues might need a richer palette of ESEs and hence a higher density 
of ESEs.  Is this true? To test for such a correlation I established a dataset of human genes 
and determined the number of tissues in which they were expressed (out of 27 tissues) 
(Supplementary table S5). I find that ESEs densities of the genes (n=15326), which have at 
least two introns, correlate positively and significantly with the proportion of tissues in 
which this gene expressed (rho = 0.06, P = 4.40 × 10
-14
). This indicates genes with higher 
ESE density tend to express in more tissues, therefore tissue-specific genes should have 
few ESEs. Tissue specific genes thus have a lower density of ESEs, which also suggests 
one might be able to ablate ESEs of tissue specific genes with little harm.  We note 
however the effect is weak, and the interpretation far from clear, as there may be 
covariance with intron size and density. 
 
5. There is relationship of tissue-specific genes with pathogenic SNPs 
Gene therapy is typically only needed to replace disease-causing genes with the wild-type 
version.  Above I have presumed that disease-associated and unassociated tissues specific 
genes are identical as regards their ESE behavior. To address this issue I cross-reference 
the 1747 genes with pathogenic SNPs identified in the previous chapter (Chapter IV) with 
tissue specific genes. By matching the IDs with the tissue-specific genes, we can calculate 
the proportion of tissue-specific genes with pathogenic SNPs in different tissues 
(Supplementary table S6). I then ask whether disease and non-disease tissue specific genes 
differ in any important parameters.  
 
I find that ESE density (using INT3) is not different (Mann Whitney U test: P = 0.25), 
while CAI (Mann Whitney U test: P = 1.78×10
-6
) and expression levels (Mann Whitney U 
test: P = 1.99× 10
-8
) are different between disease and non-disease tissue-specific genes 
(Supplementary table S6) (Fig. 2). I conclude that ESE density between disease and non-
disease tissue-specific genes is no different but codon usage bias and expression levels are 
all likely to be higher in disease-associated tissue-specific genes.  I conclude that 
conclusions as regards ESEs in disease associated tissue specific genes can probably be 






As regards the prospects of altering ESE content to manipulate transgenes the results of 
this brief analysis are largely encouraging.  There are such things are relatively tissue 
specific ESEs (prior to multi-test control) and ESE usage is not a function of expression 
level. Disease associated genes appear to behave the same as regards ESEs as non-disease 
genes. Moreover, I found genes with higher ESE density tend to express in more tissues. 
This indicates tissue-specific genes should have few ESEs, meaning it might be possible to 
delete some ESEs with little effect. Whether in practice these insights prove helpful will 
require experimental confirmation.  I note that not all tissues have an ESE particular to that 
tissue.  
  
Materials and Methods 
 
ESEs usage of tissue-specific genes  
We download tissue-specific gene information (tissue type, gene ID and expression level) 
from “The human protein atlas” (http://www.proteinatlas.org/). These genes are 
defined as “tissue-specific” (or “tissue enriched”) due to their mRNA levels in a particular 
tissue being at least five times those in all other tissues (Uhlen et al. 2015). By gene IDs 
list and our perl program, we obtain reference sequences (hg38) of tissue enriched genes in 
which there are at least 2 introns (we do this for analysis on ESE density of internal exons). 
Only those (n=1595) expressed in the tissues (n=19) that have more than 5 tissue-specific 
genes are collected for further analysis (Supplementary table S1) (Table 1). 
We obtain exon ends (if an exon is longer than 138 bp, both sides of 69 bp exon ends are 
used; otherwise the whole exon are regarded as “end region”) ESE density by calculating 
the proportion of nucleotides involved in ESEs candidate (INT3) in length of exon end 
region. Then ESEs density of a gene is the average of ESEs densities of its all internal 
exons.  
 
Codon usage bias of tissue-specific genes 
We use CAI (Codon Adaptation Index) to measure the codon usage patterns of tissue-
specific genes. First we set up a reference dataset of 155 human ribosomal protein 
encoding genes (From: RPG- the Ribosomal Protein Gene database) (Nakao, Yoshihama, 
and Kenmochi 2004), and then by “Countcodon program” 
(http://www.kazusa.or.jp/codon/countcodon.html) establish a reference codon table. CAI 
values can be calculated by a program “CAIcal” (CAIcal_ECAI_v1.4.pl) (Supplementary 
table S1).  
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Correlation analysis on ESE usage, codon usage and expression levels 
By Spearman‟s correlation analysis, we do pairwise correlation of ESEs usage (ESEs 
density based on “INT3” and “INT3+RESCUE” candidate datasets), codon usage (CAI) 
and expression levels (FPKM) (Supplementary table S2).  
 
Tissue specificity analysis on ESE usage, codon usage and expression levels 
We do a test of “homogeneity of variance” in R for ESE density, CAI and expression 
levels separately. All of them are suitable for ANOVA analysis to see whether there are 
any significant differences between independent groups (different tissues) (Supplementary 
table S3). 
 
Usage of 6-mer ESE candidates in different tissues 
In each tissue, we calculate density of each 6-mer ESE candidates based on INT3 dataset. 
Because we don‟t know if ESEs overlapping affect the result, two type of density are 
observed, one is “number of ESEs/length of exon ends”; the other one is “number of 
nucleotides in ESEs/ length of exon ends”. Density of 6-mer ESE candidates for a tissue 
comes from average of its tissue-specific genes ESE density, and genes ESE candidate 
density is from average of exons ESE candidate density. According to these data in 
different tissues (Supplementary table S4), we make heatmaps to show different usage 
patterns. 
 
To compare usage pattern of 6-mer ESE candidates across tissues in a numerically manner, 
I employ an index similar to the entropy measure tau, used before to define tissue 
specificity in expression (see e.g. (Weber and Hurst 2011)). Tau is here defined as: 
  
∑    
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     )
)    
   
 
where S(j) is the density of the ESE in genes expressed uniquely in tissue j, Smax is the 
maximum density for that ESE across all tissues and n is the number of tissues. Moreover, 
I check for significance of the tissue specificity by randomizing the numbers across the 
matrix. For any given tau value we repeat 1000 times (n) to set up a pseudo usage pattern 
across tissues, and then ask for, how often we would expect to see tau as big or bigger than 
that actually reported one (m). So, by p=(m+1)/(n+1), I can calculate P value for each ESE 
candidate (Table 2). 
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Relationship between ESEs usage and breadth of expression in tissues 
From database “The human protein atlas” (http://www.proteinatlas.org/), we download 
dataset (mcp.M113.035600-2) of human genes expression level in 27 tissues 
(Supplementary table S5). Also, ESEs densities of the genes (n=15326), which have at 
least two introns, are calculated and correlated with the proportion of tissues in which this 
gene expressed (Spearman‟s correlation analysis). 
 
Observation of the tissue-specific genes with pathogenic SNPs in different tissues 
In previous study, we defined 1747 genes with pathogenic SNPs according to experimental 
data. Then matching the IDs with tissue-specific genes in this research, we can find the 
proportion of tissue-specific genes with pathogenic SNPs in different tissues 
(Supplementary table S6). We also do boxplots to show difference of ESE density, CAI 
and expression levels between disease and non-disease tissue-specific genes 






Table 1. Tissues and their number of tissue-specific genes 
 
 
No. Tissue Number of tissue-specific genes 
1 adipose tissue 17 
2 adrenal gland 30 
3 bone marrow 60 
4 cerebral cortex 249 
5 esophagus 34 
6 fallopian tube 46 
7 heart muscle 27 
8 kidney 51 
9 liver 152 
10 lung 17 
11 pancreas 38 
12 placenta 64 
13 prostate 16 
14 salivary gland 33 
15 skeletal muscle 89 
16 skin 60 
17 stomach 20 
18 testis 573 
19 thyroid gland 19 
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Table 2. Non-homogeneous usage of 6-mer ESE candidates across different tissues 
Type 1 ESE density
a
  Type 2 ESE density
b
 
ESE_6_mer Tau P_value  ESE_6_mer Tau P_value 
       
AAGAAT 0.8956 0.0100  AAGAAT 0.8956 0.0110 
AACCAG 0.8864 0.0200  AACCAG 0.8864 0.0180 
AACTGG 0.8615 0.0619  AACTGG 0.8615 0.0470 
GGAAGA 0.8512 0.0739  GGAAGA 0.8512 0.0589 
GAGGAA 0.8340 0.0929  GAGGAA 0.8340 0.0889 
GAAGTA 0.8301 0.0949  GAAGTA 0.8301 0.0929 
AGAAGT 0.8305 0.0949  AGAAGT 0.8305 0.0929 
AACAAC 0.8179 0.1069  GTTGGA 0.8165 0.1149 
GTTGGA 0.8164 0.1089  AACAAC 0.8168 0.1149 
GAAGAC 0.8139 0.1159  GAAGAC 0.8139 0.1209 
GACATC 0.8060 0.1299  GACATC 0.8060 0.1309 
GGAGGA 0.8021 0.1339  CCTGGA 0.7965 0.1538 
CCTGGA 0.7965 0.1419  GGAGGA 0.7959 0.1538 
ACTGGA 0.7933 0.1518  ACTGGA 0.7933 0.1588 
GACGAA 0.7867 0.1668  GACGAA 0.7867 0.1768 
AGACGA 0.7848 0.1728  AGACGA 0.7848 0.1868 
AAGAAC 0.7762 0.1898  AAGAAC 0.7762 0.2048 
GAAGGA 0.7749 0.1918  GAAGGA 0.7746 0.2108 
AGAAAC 0.7551 0.2458  AGAAAC 0.7551 0.2727 
GACCTG 0.7472 0.2667  GACCTG 0.7472 0.2997 
GAAGAA 0.7439 0.2757  GAAGAA 0.7370 0.3287 
GAAGAG 0.7354 0.3077  GAAGAG 0.7352 0.3347 
TGAAGA 0.7343 0.3117  TGAAGA 0.7343 0.3417 
TCCTGG 0.7288 0.3247  TCCTGG 0.7288 0.3556 
AACTAC 0.7124 0.3846  AACTAC 0.7124 0.4026 
CGAGGA 0.7076 0.4076  CGAGGA 0.7077 0.4206 
AGTGAC 0.7019 0.4386  AGTGAC 0.7019 0.4476 
TCAAGA 0.7006 0.4416  TCAAGA 0.7006 0.4525 
TACCTG 0.6947 0.4665  TACCTG 0.6947 0.4745 
GCAGAA 0.6940 0.4705  GCAGAA 0.6940 0.4775 
ATTGGA 0.6884 0.4935  ATTGGA 0.6884 0.4945 
AACTTC 0.6858 0.5025  AACTTC 0.6858 0.4985 
GAGGAT 0.6795 0.5285  GAGGAT 0.6795 0.5235 
CGAAGA 0.6643 0.5804  CGAAGA 0.6643 0.5924 
AGAGAA 0.6577 0.5984  AGAGAA 0.6577 0.6184 
CTGAAG 0.6565 0.6024  CTGAAG 0.6565 0.6194 
CAGAAG 0.6463 0.6444  CAGAAG 0.6463 0.6523 
ATCTGC 0.6462 0.6464  ATCTGC 0.6462 0.6533 
GACTTC 0.6454 0.6494  GACTTC 0.6454 0.6563 
AACAGA 0.6370 0.6793  AACAGA 0.6370 0.6883 
AAGAAA 0.6332 0.6883  AAGAAA 0.6327 0.7003 
GAGGAG 0.6262 0.7203  AATGAC 0.6261 0.7193 
AATGAC 0.6261 0.7213  AGGAAC 0.6205 0.7313 
AGGAAC 0.6205 0.7353  AACCTG 0.6199 0.7333 
AACCTG 0.6199 0.7373  AAGGAA 0.6175 0.7433 
AAGGAA 0.6178 0.7493  TGAGAA 0.6150 0.7493 
TGAGAA 0.6150 0.7582  GAGGAG 0.6130 0.7552 
CAAAGA 0.6123 0.7692  CAAAGA 0.6123 0.7572 
GAAAGA 0.6005 0.8072  TGAAGG 0.6005 0.7902 
TGAAGG 0.6004 0.8072  GAAAGA 0.6000 0.7912 
GAAACT 0.5982 0.8152  GAAACT 0.5982 0.7962 
GAAGTT 0.5954 0.8262  GAAGTT 0.5954 0.8032 
ACAGAA 0.5942 0.8302  ACAGAA 0.5942 0.8082 
GAAGCA 0.5933 0.8342  GGAGAT 0.5927 0.8112 
GGAGAT 0.5927 0.8352  GAAGCA 0.5933 0.8112 
GAAGAT 0.5904 0.8402  GAAGAT 0.5904 0.8182 
TGAAGC 0.5867 0.8511  TGAAGC 0.5867 0.8322 
AGAAGC 0.5836 0.8541  AAGGAC 0.5839 0.8392 
AAGGAC 0.5839 0.8541  AGAAGC 0.5836 0.8422 
AAGAGA 0.5827 0.8551  AAGAGA 0.5823 0.8462 
AGAGGA 0.5759 0.8651  AAGAAG 0.5765 0.8551 
GCAAGA 0.5727 0.8761  AGAGGA 0.5759 0.8561 
AGAAGA 0.5726 0.8761  GCAAGA 0.5727 0.8661 
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TGTGGA 0.5693 0.8831  TGTGGA 0.5693 0.8781 
GATGGA 0.5675 0.8891  AGAAGA 0.5676 0.8841 
CAAGAA 0.5586 0.9101  GATGGA 0.5659 0.8891 
TTGGAT 0.5540 0.9191  CAAGAA 0.5586 0.9061 
AAGAAG 0.5535 0.9211  TTGGAT 0.5541 0.9101 
GATGAA 0.5404 0.9421  GATGAA 0.5404 0.9251 
AAGACA 0.5382 0.9451  AAGACA 0.5382 0.9281 
GAGAAG 0.5258 0.9570  GAGAAG 0.5257 0.9451 
CAAGAT 0.5222 0.9640  CAAGAT 0.5222 0.9481 
AAAGAA 0.5152 0.9690  AAAGAA 0.5172 0.9550 
GAGAAA 0.4961 0.9790  GAGAAA 0.4961 0.9710 
GATGCA 0.4905 0.9800  GATGCA 0.4905 0.9770 
GACCAG 0.4787 0.9870  GACCAG 0.4787 0.9820 
AAAGGA 0.4788 0.9870  AAAGGA 0.4788 0.9820 
GGAGCA 0.4708 0.9910  GGAGCA 0.4708 0.9840 
CAAGGA 0.4668 0.9920  AATGGA 0.4682 0.9840 
GGAGAA 0.4644 0.9920  CAAGGA 0.4668 0.9850 
AAGATC 0.4557 0.9920  GGAGAA 0.4644 0.9860 
AATGGA 0.4682 0.9920  AAGATC 0.4557 0.9910 
GTGAAG 0.3950 0.9980  ACAAGA 0.4176 0.9980 
ACAAGA 0.4167 0.9980  GTGAAG 0.3950 1.0000 
a: ESE density = number of nucleotides in ESEs/length of exon ends 








Fig. 1 heatmaps to show different usage patterns of 6-mer ESE candidates 
(a) heatmap showing different usage patterns of 6-mer ESE candidates (number of 















(b) heatmap showing different usage patterns of 6-mer ESE candidates (number of 


























Fig. 2 difference of ESE density, CAI and expression levels between disease and non-
disease tissue-specific genes 
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Chapter VI. Discussion 
 
While it is tempting to suppose that the evolution of a gene is largely dictated by selection 
on the protein product, it is now clear that much selection is also involved in the 
manufacture of the product (Chamary and Hurst 2005; Carlini and Genut 2006; Hurst 2006; 
Nackley et al. 2006; Parmley, Chamary, and Hurst 2006; Parmley et al. 2007; Warnecke, 
Weber, and Hurst 2009; Bartoszewski et al. 2010; Brest et al. 2011; Cáceres and Hurst 
2013; Gartner et al. 2013; Lawrie et al. 2013).  At least in humans (or mammals more 
generally) splice-related constraints feature strongly in this manufacture side of the 
equation. But are all species with introns equally affected?  Are all genes or exons equally 
affected? If we can predict which exons have more splice support can we also predict 
which exons, and where in exons, disease associated mutations occur? In my thesis, I 
address such issues using both intra and inter-specific analysis.  
 
In my first analysis I follow up on the suggestion, from both experimental and comparative 
analysis, that large introns are harder to splice accurately. For instance, splice rates 
decrease if extra sequence is experimentally inserted into introns (Klinz and Gallwitz 1985; 
Luehrsen and Walbot 1992; Fox-Walsh et al. 2005; Sironen et al. 2006) and, by splicing 
assays, the exons flanked by large introns are found to be the hardest ones to splice 
consistently (Bell et al. 1998; Fox-Walsh et al. 2005). By contrast, exons flanked by short 
introns, also associated with high expression levels, tend to be subject to less noisy splicing 
(Pickrell et al. 2010), and short introns may overcome the poor recognition of alternatively 
spliced exons (Bell et al. 1998). In addition, exons flanked by long introns tend to be those 
most commonly lost during evolution (Kandul and Noor 2009), consistent with splice error 
rates being too high to sustain the exon. To provide a possible explanation, we conjecture 
that if the flanking intron is large, the splice site is harder to recognize and the possibility 
for cryptic splice sites contained within the intron would be higher. Thus the true splice 
sites need to be reinforced by binding of SR proteins to ESEs. 
 
A problem with prior comparative analyses is that they had no non-vertebrate genomes 
with large introns with which to test a possible coupling between intron size and ESE 
usage. In chapter II I report on splice-related cis-motif usage analysis of the Ectocarpus 
genome, which is a species phylogenetically very distant from vertebrates but, like 
vertebrates in having abundant large introns. In Ectocarpus, patterns of codon and amino 
acid usage and k-mer enrichments in the vicinity of exon boundaries resemble that of 
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humans. This indicates a deep phylogenetic conservation of exonic splice-related 
constraints. Moreover, while I identified SR proteins that Ectocarpus appears to employ, it 
would be a helpful follow on study to ask whether certain SR proteins define certain trends 
through their binding preferences.  Likewise it would be good to have experimental 
confirmation of the ESEs that Ectocarpus employs and to see whether the particular SR 
protein binding motifs are themselves conserved.  
 
My analysis on Ectocarpus has left one outstanding mystery, namely why Ectocarpus has 
so many more codons and amino acids showing strong preference avoidance trends (and 
also so many putative ESEs) than humans. I postulated a low rate of alternative splicing in 
Ectocarpus as a possible factor.  At first sight this seems like a good suggestion as 
Ectocarpus is unusual in having multiple large introns and a low rate of alternative splicing, 
making it all but unique amongst well described genomes.  However, when I considered a 
more phylogenetically extensive and explicit framework (Chapter III) I observed no 
relationship between alternative splicing rates and cis-motif usage. This analysis can 
certainly be questioned as alternative splicing rate estimation was only possible for a 
limited sample of the taxa and tends also to be highly dependent on transcriptome depth.  
The data I employed attempts to avoid the problem of transcriptome depth, but nonetheless 
I expect that for lesser described species the estimates may well be inaccurate. Nonetheless, 
this analysis provided no support for the notion that motif usage is a function of alternative 
splice rates leaving the remarkable enrichment seen in Ectocarpus all the more unexpected 
and unexplained.  
 
Another important finding from Ectocarpus genome is that splice optimal and 
translationally optimal codons are not always mutually exclusive, which is different from 
what is seen in Drosophila (Warnecke and Hurst 2007). One possible reason is that, in 
Drosophila, selection for translational optimality is stronger than that in Ectocarpus. This 
is supported by the observation that, in Ectocarpus, the correlation between CAI and 
expression level is rather weak.  Given this, selection to force divergence between 
translationally optimal and splice optimal codons may also be weak. Another possibility is 
that the observation in Drosophila is an accidental consequence of selection on 
translational optimality and splice optimality happening to go in opposite directions. We 
also need to be cautious here as the expression data that I employed is much more limited 
than that for Drosophila.  Moreover, repeating the analysis using an array based expression 
data set I couldn‟t repeat the finding of a correlation between codon usage and expression 
level (data not presented).  However, this evidence needs to be treated with considerable 
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caution.  On discussing the data with the curator (Simon Dittami) of this data source (A-
MEXP-1445 Nimblegen E.siliculosus Gene Expression v1: http://www.ebi.ac.uk/arrayexpress/arrays/A-
MEXP-1445), I was advised to employ EST-matching method to estimate gene expression, 
because that microarray is not based on the genome, but on available EST libraries. While 
the EST data then is the best currently available, strong conclusions need stronger data. 
 
The concentration in Chapter III was not so much the relationship between alternative 
splicing and ESE usage, but rather more generally the predictors of cis motif usage across 
taxa. As a novel extension to the nearly neutral hypothesis, I suggested that selection can 
sometimes be stronger when effective population sizes are small (Chapter III). The model 
proposed that reduced Ne might lead to larger and more introns (following the suggestion 
of Lynch and Conery), this makes it harder to correctly identify splice sites, which in turn 
could lead to stronger selection for motifs that inhibit the increase in the degree of error-
prone splicing. One ambiguity in our model is the relationship between intron size, ESE 
enrichment and splice site strength.  ESEs are usually found in proximity to weak splice 
sites.  But were the sites weak because of decay (e.g. in low Ne conditions) or weak 
because ESE enforcement means that it is no longer so crucial to have strong splice sites? 
 
Importantly we find that our measures of Ne.μ do correlate with intronic dimensions in a 
phylogenetically explicit framework, whilst the original measures employed by Lynch and 
Conery do not (as previously pointed out) (Whitney and Garland 2010). It also seems clear 
that cis-motif usage and intronic dimensions covary within and between genomes. As 
regards the former we find, in the human genome, that there are more ESE-related 
synonymous sites of exon ends under selection when exons are flanked by larger introns; 
meanwhile, intronic dimensions and splice site usage predict cis-motif usage across species 
and Ne.μ predicts intronic dimensions and splice site usage. Furthermore, we find that 
intra-specifically, exons flanked by large introns both have higher ESE density and greater 
usage of AGgt, consistent with coevolution between splice site, ESEs and intron size. 
Therefore, our hypothesis seems to be reasonable as a complement of the nearly neutral  
hypothesis.  
 
However, some uncertain factors should also be noticed.  For example, Ne.μ is estimated 
based on polymorphism of orthologous genes, so selection of genes analysed could affect 
final results. Moreover there might be a systematic issue with all polymorphism based 
attempts to estimate Ne.μ, this being that the expected correlation between Ne and 
heterozygozity appears to be much weaker than predicted by the neutral model (which 
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forms the basis for Ne.μ estimation), but is consistent with the effects of more common 
hitchhiking in genomes in large populations (Corbett-Detig, Hartl, and Sackton 2015). 
Nonetheless, we observe that Ne.μ robustly predicts intronic dimensions and splice site 
usage, suggesting that it is perhaps not too poor an estimator.  
 
Although we consider rate of alternative splicing, in our previous study on brown algae 
Ectocarpus, as a factor to explain higher proportion of codons and amino acids showing 
skews in usage in exon ends (Wu et al. 2013), we do not observe any relationship between 
cis-motif usage and alternative splicing rates in human genome. Also, whether there is a 
significant difference in ESE density between alternative and constitutive exons is still up 
in the air (Ke et al. 2011; Cáceres and Hurst 2013). To date, no strong prior evidence has 
been found that ESE usage is a modulator of alternative splicing and particularly strong 
purifying selection on ESEs has been excluded as an explanation for the especially low 
rate of evolution of conserved alternative exons (Parmley, Chamary, and Hurst 2006; 
Cáceres and Hurst 2013). The current data thus suggest that ESE usage allows 
determination of splice sites once the “decision” to splice a given exon is made, rather than 
suggesting that ESEs act as elements to control alternative splicing decisions. 
 
To understand an unexpected result that in the between-species comparison, intron size is 
by no means the best intron-dimension predictor of cis-motif usage (intron density is better 
than mean intron size, and a combination of size and density is the best predictor), we 
propose a decoy splice spite model as a potential explanation. This model correctly 
predicts (or explains) intragenomic and intragenic trends, highlighting the selection on 5‟ 
exons being more acute than that on 3‟ exons. Indeed, this intra-gene bias distribution of 
selection is consistent with the observation when we investigate occurrence of pathogenic 
SNPs (Chapter IV).  
 
More generally, when we explore the relationship between determinants of the usage of 
splice-associated cis-motifs and the distribution of human pathogenic SNPs, we find a 
strong enrichment of pathogenic SNPs at exon ends. From this we infer that these SNPs 
interfere with splicing. Beyond this as pathogenic SNPs tend to reside in exon with few 
ESEs, we propose a “fragile” exon model (Chapter IV).  Note however, that our inferences 
here are at arms length – we never actually analyse RNASeq libraries of normal and 
pathogenic tissues. Detailed analysis in several cases has been performed (Krawczak, 
Reiss, and Cooper 1992; Nissim-Rafinia and Kerem 2002; Faustino and Cooper 2003; 
Chamary, Parmley, and Hurst 2006), so a possible connection between splicing and 
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disease is by no means unexpected.  Whether our estimates of the proportion of pathogenic 
SNPs associated with splicing is correct would require an intensive sampling of splice 
forms associated with disease causing SNPs, comparing normal and wild type samples to 
identify the novel splice forms.  In addition, to confirm any of these it would be necessary 
to take an appropriate cell line, remove the wild-type form of the gene, transgenically add 
the “mis-splicing” form and show deleterious effects consistent with disease pathology.  
Such experimental analyses are far beyond the domain of this thesis. 
 
My final chapter (Chapter V) is a rather preliminary and exploratory analysis.  In this I ask 
whether tissue specific genes have ESEs that might be especially commonly used in that 
given tissue.  In part the motivation here is biotechnological more than evolutionary. 
Nonetheless, the finding that some ESEs seem to be especially enriched in genes expressed 
in certain tissues is worthy of further scrutiny.  It would for example, be helpful to see if, 
when we look at genes expressed in just two tissues we could predict the ESE usage from 
the analysis of single tissue expressed genes alone.  Likewise we can ask whether ESE 
density as a whole is correlated with tissue specificity.  A particularly elegant way of 
confirming my preliminary observation would be to consider tissue specific exons and ask 
if these too use the “tissue specific ESEs”.  
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